Simon Cooper received his Ph.D. in Radiation/Oncology and has since focused his research career on translating scientific findings into clinical applications while emphasizing patient care. He has authored multiple peer-reviewed articles in collaboration with clinicians and currently leads pre-clinical studies at Mayo Clinic Florida identifying potential new cancer therapies. Cooper aims to continue interacting with clinical researchers to advance innovative patient care.

1. S.J. COOPER | Page 1 of 4
SIMON JAMES COOPER, PH.D.
sjcooper7@gmail.com
BACKGROUND
After receiving my Ph.D. in Radiation/Oncology, my research career has focused on translating scientific
findings from bench to bedside while emphasizing patient care. My goals include continuing to interact with the
clinical community to further delivery of cutting-edge patient care. While collaborating with clinicians, I share my
knowledge of basic scientific techniques, potential markers of disease, and innovative diagnostic tests. I am a
skilled research presenter and have published scientific review and peer-reviewed articles. I have formed strong
bonds with many leading clinicians to collaboratively identify novel biomarkers of disease during my work
developing pre-clinical models for cancer therapy, for which I wrote grants and was awarded funding. I look
forward to sharing my passion for the translation of important clinical advances to any audience.
WORK EXPERIENCE
Research Associate, Mayo Clinic Florida | 2011 - present
 Authored peer-reviewed translational research articles published in The Journal of Molecular Biomarkers
and Diagnosis and The Journal of Molecular Cancer Therapeutics in collaboration with several Mayo Clinic
clinicians. Also wrote and edited grant applications for submission to the NIH and Mayo Clinic internal
funding mechanisms using translational findings and clinical collaborations.
 Led pre-clinical laboratory based studies identifying potential new therapeutic drug combination for the
treatment of triple negative breast cancer and clear cell renal cell carcinoma (ccRCC). These investigations
are being transitioned into Phase I/II clinical trials.
 Performed Ad Hoc review for journals like Cancer Research, Oncogene, and Molecular Cancer Research.
Senior Research Fellow, Mayo Clinic Florida | 2006 - 2011
Senior Research Associate, Arizona Cancer Center | 2001 - 2006
Postdoctoral Scholar, University of Kentucky | 1999 - 2001
EDUCATION
 Ph.D., Radiation/Oncology | August 1995 - December 1998
University of Wolverhampton, England and the University of Kentucky
 B.Sc., Honours, Biomedical Sciences | September 1993 - June 1995
University of Wolverhampton, England
 HND (Higher National Diploma), Applied Biology | September 1991 - June 1993
Wolverhampton Polytechnic, England
HONORS AND AWARDS
Arizona Cancer Center AACR Travel Award | AACR Annual Meeting, Washington, D.C. | 2006
Pfizer Scholar-in-Training Award | Frontiers of Cancer Prevention Conference, Phoenix, AZ | 2003
Physiological Society Summer Research Award | University of Wolverhampton | 1995
PROFESSIONAL MEMBERSHIPS AND SOCIETIES
Associate Member American Association for Cancer Research (AACR) | 2006 – present

2. S.J. COOPER | Page 2 of 4
TEACHING AND MENTORING
 Research Mentor for Yilin Zhang (SURF student 2006-2008), Greg Kennedy (SURF student 2009-2011),
Hege Larsen (exchange student 2009-2010), Michelle Hoffman (Ph.D. rotation student 2011), Prakash
Vishnu, M.D. (2010-2011), Jacob Mathew, M.D. (2011-present), Christina von Roemeling (Research
Technician 2008-present) and Stephen Rohl (Special Projects Associate 2009-2012).
 Lab Captain. MEDCAMP Program through the College of Medicine, University of Arizona (2004-2006).
 Research Mentor for Neale Hanke, undergraduate at the University of Arizona. Study for credit (2006).
 Guest Lecturer. Southwest Environmental Health Sciences Center-Community Outreach and Education
Program. College of Pharmacy, University of Arizona (2005).
 Research Supervisor for Nancy Kim, Medical Student, College of Medicine, University of Arizona (2003)
and Thomas Maglinao, undergraduate in the Minority Health Disparities Summer Research Program,
University of Arizona (2003).
 Guest Lecturer. Clinical Immunology, CLS 855. School of Allied Health Professionals, University of
Kentucky (1998).
 Guest Lecturer. Seminars in Advanced Hematology, CLS 501. School of Allied Health Professionals,
University of Kentucky (1995-1997).
PUBLICATIONS
Peer-reviewed Publications
Simon J. Cooper, Christina Von Roemeling, Kylie H. Kang, Laura A. Marlow, Michael Menefee, Han W. Tun,
Edith Perez, John A. Copland. Romidepsin and decitabine synergistically induce apoptosis in clear cell renal cell
carcinoma and triple negative breast cancer cells through the re-expression of sFRP1. Molecular Cancer
Therapeutics. Oct: 11(10): 2105-15, 2012.
Marlow LA, von Roemeling CA, Cooper SJ, Zhang Y, Rohl SD, Arora S, Gonzales IM, Azorsa DO, Reddi HV,
Tun HW, Döeppler HR, Storz P, Smallridge RC, Copland JA. Foxo3a drives proliferation in anaplastic thyroid
carcinoma via transcriptional regulation of cyclin A1: A paradigm shift that impacts current therapeutic
strategies. J Cell Sci. Sep 15: 125(Pt18): 4253-63, 2012.
Dickinson SE, Olson ER, Zhang J, Cooper SJ, Melton T, Criswell PJ, Casanova A, Dong Z, Hu C, Saboda K,
Jacobs ET, Alberts DS, Bowden GT. p38 MAP kinase plays a functional role in UVB-induced mouse skin
carcinogenesis. Molecular Carcinogenesis, Jun: 50(6): 469-78, 2011.
Armstrong MD, Von Hoff D, Barber B, Marlow LA, von Roemeling C, Cooper SJ, Travis P, Campbell E, Paz-
Fumagalli R, Copland JA, Colon-Otero G. An effective personalized approach to rare tumor: prolonged survival
in metastatic pancreatic acinar carcinoma based on genetic analysis and cell line development. J Cancer, Mar
8: 2: 142-52, 2011.
Jiang L, Marlow LA, Cooper SJ, Roemeling CV, Menke DM, Copland JA, Tun HW. Selective central nervous
system tropism of primary central nervous system lymphoma. Int J Clin Exp Pathol, Oct 8: 3(8): 763-7, 2010.
Marlow LA, D'Innocenzi J, Zhang Y, Rohl SD, Cooper SJ, Sebo T, Grant C, McIver B, Kasperbauer JL,
Wadsworth JT, Casler JD, Kennedy PW, Highsmith WE, Clark O, Milosevic D, Netzel B, Cradic K, Arora S,
Beaudry C, Grebe SK, Silverberg ML, Azorsa DO, Smallridge RC, Copland JA. Detailed Molecular
Fingerprinting of Four Anaplastic Thyroid Carcinoma Cell Lines and Their Use for Verification of RhoB as a
Molecular Therapeutic Target. J Clin Endocrinol Metab. Dec; 95(12): 5338-47, 2010.
Cooper SJ, Zou H, Legrand SN, Marlow LA, von Roemeling CA, Radisky DC, Wu KJ, Hempel N, Margulis V,
Tun HW, Blobe GC, Wood CG, Copland JA. Loss of type III transforming growth factor-beta receptor expression
is due to methylation of the transcription factor GATA3 in renal cell carcinoma. Oncogene, 29(20); 2905-2915,
2010.
Tun HW, Marlow LA, von Roemeling CA, Cooper SJ, Kreinest P, Wu K, Luxon BA, Sinha M, Anastasiadis PZ,
Copland JA. Pathway signature and cellular differentiation in clear cell renal cell carcinoma. PLoS One. May
18;5(5):e10696.2010.

3. S.J. COOPER | Page 3 of 4
Marlow LA, Reynolds LA, Cleland AS, Cooper SJ, Gumz ML, Kurakata S, Fujiwara K, Zhang Y, Sebo T, Grant
C, McIver B, Wadsworth JT, Radisky DC, Smallridge RC, Copland JA. Reactivation of suppressed RhoB is a
critical step for the inhibition of anaplastic thyroid cancer growth. Cancer Research, 69(4); 1536-44, 2009.
Margulis V, Maity T, Zhang X, Cooper S, Copland J, Wood C. Type III TGF-β receptor mediated apoptosis in
renal cell carcinoma independent of the canonical TFG-β signaling pathway. Accepted: Clinical Cancer
Research. May 2008.
Hempel N, How T, Cooper SJ, Green TR, Dong M, Copland JA, Wood CG, Blobe GC. Expression of the Type
III TGF- {beta} Receptor is negatively regulated by TGF- {beta}. Carcinogenesis, 29(5); 905-12, 2008.
Howard P. Glauert, Aysegul Eyigor, Job C. Tharappel, Simon Cooper, Eun Y. Lee, and Brett T. Spear (2006).
Inhibition of Hepatocarcinogenesis by the Deletion of the p50 Subunit of NF-B in Mice Administered the
Peroxisome Proliferator Wy-14,643. Toxicological Sciences, 90(2); 331-6.
Cooper S. J., Bowden G. T. (2005). Differential Inhibition of UVB Induced AP-1 and NF-B Transactivation by
Components of the Jun bZIP Domain. Molecular Carcinogenesis, 43(2); 108-16.
Simon J. Cooper*, Michael A. Bachelor*, Ewa T. Sikorski and G. Timothy Bowden (2005). Inhibition of p38
MAPK and PI3-Kinase Decreases UVB-Induced AP-1 and COX-2 in a SKH-1 Hairless Mouse Model. Molecular
Cancer Research, 3(2); 90-99. *Equal contribution.
Ming Zhu, Yeusheng Zhang, Simon Cooper, Ewa Sikorski, John Rohwer, G. Timothy Bowden (2004). Phase II
enzyme inducer, Sulforaphane, inhibits UVB-induced AP-1 activation in human keratinocytes by a novel
mechanism. Molecular Carcinogenesis, 41; 179-186.
Cooper SJ, MacGowan J, Ranger-Moore J, Young MR, Colburn NH, Bowden GT. (2003). Expression of
dominant negative c-jun inhibits ultraviolet B-induced squamous cell carcinoma number and size in an SKH-1
hairless mouse model. Molecular Cancer Research, 1(11); 848-54.
Li Y, Tharappel JC, Cooper S, Glenn M, Glauert HP, Spear BT (2000). Expression of the hydrogen peroxide-
generating enzyme fatty acyl CoA oxidase activates NF-kappaB. DNA Cell Biology, 19(2); 113-20.
Cooper SJ, Gass C, Birch NJ, Phillips JD, Gallicchio VS, Doukas MA (2000). Production by a murine bone
marrow stroma cell of stem cell factor (SCF) is inhibited by exposure to lithium and/or radiation. Journal of Trace
and Microprobe Techniques, 18(4); 583-592.
Cooper SJ, Gass C, Bryson S, DelaPuca R, Birch NJ, Gallicchio VS, Doukas MA (1998). Radiomodulation by
lithium on marrow stromal support of granulopoiesis. Journal of Trace and Microprobe Techniques, 16(2); 9-16.
Review Articles
Simon J. Cooper, Han W. Tun, Stephen M. Roper, Yunee Kim, Thomas Kislinger, Richard R. Drake, John A.
Copland. Current status of biomarker discovery in human clear cell renal cell carcinoma. J Mol
Biomark Diagn S2:005. doi:10.4172/2155-9929.S2-005 2012.
Cooper SJ, Bowden GT. Ultraviolet B regulation of Transcription factor families: roles of nuclear factor-kappa B
(NF-kappaB) and activator protein-1 (AP-1) in UVB induced skin carcinogenesis. Curr Cancer Drug Targets, 7
(4);325-34, 2007.
Book Chapters
SJ Cooper, C Gass, NJ Birch, JD Phillips, VS Gallicchio, MA Doukas (1999).
Production by a murine marrow stroma cell of stem cell factor (SCF) is inhibited by exposure to lithium and/or
radiation. In: Lithium – 50 Years: Recent advances in Biology and Medicine. (Eds) Lucas KC, Becker RW
and Gallicchio VS, pp 219-230, Weidner Publishing, Cheshire, Connecticut.
PRESENTATIONS
Oral Presentations
 Post-doctoral seminar series, Mayo Clinic Jacksonville (2011) “A role for GATA3 in clear cell renal cell
carcinoma.”

4. S.J. COOPER | Page 4 of 4
 Post-doctoral seminar series, Mayo Clinic Jacksonville (2011) “NPTX2: a novel molecular target for therapy
in clear cell renal cell carcinoma.”
 Post-doctoral seminar series, Mayo Clinic Jacksonville (2009) “GATA3 is a critical transcription factor for
differentiated function in the kidney.”
 Cell Signaling Meeting, South Padre Texas (2008) “Regulation of the Human Type III TGF Receptor.”
 Post-doctoral seminar series, Mayo Clinic Jacksonville (2008) “Transcriptional Regulation of the Human
Type III TGF Receptor.”
 Cell Signaling Meeting, South Padre Texas (2007) “Transcriptional Regulation of the Human Type III TGF
Receptor.”
 Cancer Prevention and Control Grand Rounds Seminar, Arizona Cancer Center (2004) “Identification of
potential molecular targets for the chemoprevention of UVB-induced skin carcinogenesis.”
 Cancer Prevention and Control Grand Rounds Seminar, Arizona Cancer Center (2002) “Role of AP-1 and
NF-B in UVB induced skin carcinogenesis.”
 Invited Seminar, Arizona Cancer Center (2001) “Transgenic models to study NF-B in the response to
peroxisome proliferators.”
 Department of Microbiology and Immunology, University of Kentucky (2001) “Transgenic models to study
NF-B in the response to peroxisome proliferators.”
 50th Anniversary of Lithium Conference, Lexington KY (1999) “Production by a representative of the murine
haematopoietic bone marrow stroma of the soluble form of the cytokine stem cell factor (SCF) is inhibited by
exposure to lithium and/or radiation.”
Poster Presentations
 AACR Annual Meeting (Orlando, 2011) “Negative transcriptional regulation of the human type III TGF
receptor in ccRCC. Cooper SJ.”
 AACR Annual Meeting (San Diego, 2008) “Transcriptional regulation of the human type III TGF receptor.
Cooper SJ.”
 Nineteenth International Conference on Antiviral Research (San Juan, Puerto Rico, 2006) “Inhibition of
Murine Cytomegalovirus by Second Generation Ribonucleotide Reductase Inhibitors Didox and Trimidox.
Mohammed Inayat, Simon Cooper, Donald Smee, Vincent Gallicchio, Beth Garvey, Howard Elford, Oliver
Oakley.”
 AACR Annual Meeting (Washington, D.C., 2006) “Activation of NF- B by Ultraviolet light B is through two
different phosphorylation events of its inhibitor molecule I B . Simon J Cooper.”
 Proceedings of the Frontiers of Cancer Prevention Research Conference (Phoenix, Arizona, 2003) “A
dominant negative c-jun (TAM67) interacts with members of the NF-B protein family inhibiting UVB induced
NF-B transactivation. Simon J Cooper.”
 Proceedings of the Frontiers of Cancer Prevention Research Conference (Phoenix, Arizona, 2003)
“Modulation of p38 and PI-3 Kinase following acute UVB exposure in SKH-1 mouse epidermis. Michael A.
Bachelor, Simon J Cooper, Ewa Sikorski and G. Tim Bowden.”
 Experimental Biology 2001 (Orlando, Florida, 2001) “Mouse models to explore the role of NF-B in the
response to peroxisome proliferators. Simon Cooper.”
 AACR Annual Meeting (New Orleans, 1998) “Amifostine and its active metabolite WR-1065 prevent the
acute phase irradiation response of bone marrow stroma, as measured by stromal support and
hematopoietic progenitors. Simon Cooper.”
 Life Sciences Research Day, University of Kentucky (1997) “Radiomodulation by lithium in marrow support
of granulopoiesis. Simon Cooper.”
AWARDED RESEARCH GRANTS
 A Diagnostic Tool for Micrometastatic Disease in ccRCC.
Mayo Clinic Marriot Award | Type: Developmental
 Identification of Potential Agents That Block the Interactions between the Transcription Factors NF-
B and AP-1: Two Families of Transcription Factors That Are Involved in the Promotion of UVB
Induced Squamous Cell Carcinoma of the Skin.
Cancer Research Foundation of America | Type: Fellowship
REFERENCES AVAILABLE UPON REQUEST